Has Tripti Singh, MD received payments from drug or device companies?

Yes. Drug and device makers reported $13,369 in general payments to Tripti Singh, MD across 16 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Tripti Singh, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Tripti Singh, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Tripti Singh, MD

Nephrology · Fitchburg, WINPI 1528218781

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (50.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Travere Therapeutics, Inc. at 28.5% of the total. Among nephrology clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$13,369in general payments, 2019–2025

Across 16 payments — averaging $835.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Travere Therapeutics, Inc.$4K
Aurinia Pharma U.S., Inc.$4K
Otsuka Pharmaceutical Development & Commercialization, Inc.$3K
Novartis$3K
Apellis Pharmaceuticals, Inc.$141
Outset Medical Inc$75
plus $78 from 2 others

$199,736in research payments, 2019–2025

Across 55 payments — averaging $3631.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$74K
Otsuka Pharmaceutical Development & Commercialization, Inc.$53K
Alnylam Pharmaceuticals Inc.$33K
Mallinckrodt Enterprises LLC$23K
Gilead$13K
Mallinckrodt Hospital Products Inc.$4K

What the payments were for

Consulting fees$5,52041%
Speaking & faculty fees$6,77051%
Travel & lodging$2252%
Food & beverage$8546%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Travere Therapeutics, Inc.	5	$3,810
Aurinia Pharma U.S., Inc.	3	$3,627
Otsuka Pharmaceutical Development & Commercialization, Inc.	1	$2,920
Novartis	2	$2,718
Apellis Pharmaceuticals, Inc.	1	$141
Outset Medical Inc	2	$75
Calliditas Therapeutics US Inc.	1	$55
Fresenius USA Marketing, Inc.	1	$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

LUPKYNIS$3,627
Fabhalta$2,718
Vanrafia$2,600
Empaveli$141

How this compares

$13,369 in reported general payments places this provider in the 90th percentile of 173 nephrology providers in Wisconsin.

See all nephrology providers in Wisconsin →

Medicare billing

Part B allowed, 2024

$136,900

Medicare patients

243

Services billed

929

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
FarxigaDapagliflozin Propanediol	27	$32,351
Sevelamer Carbonate	27	$4,108
Clonidine	14	$1,836
Mycophenolate Mofetil	19	$1,415
Nifedipine ErNifedipine	43	$951
Midodrine Hcl	12	$702
Tacrolimus	11	$558
Lisinopril	103	$530
Losartan Potassium	53	$520
Amlodipine Besylate	50	$450
Furosemide	43	$401
Hydralazine Hcl	26	$280
Carvedilol	28	$270
Allopurinol	12	$233
Spironolactone	27	$230

Paid to pharmacies, not to this prescriber.

Other nephrology in Fitchburg

Micah ChanFitchburg$80K
Fahad AzizFitchburg$17K
Ali GardeziFitchburg$16K
Sarah PanzerFitchburg$5K
Kevin RegnerMilwaukee$246K
Rosanna RanieriKenosha$84K
Rishi KoraGlendale$57K
Manohar AhujaMilwaukee$35K
Ashraf El MeanawyMilwaukee$30K
Anna GaddyMilwaukee$28K

See the full list for Wisconsin →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →